Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
The overexpression of myeloid cell leukemia-1 (MCL-1) has been identified in numerous hematologic malignancies and solid tumors. Currently, there are no selective MCL-1 inhibitors. Here, we present a case of left kidney undifferentiated spindle cell sarcoma with MCL-1 amplification. The tumor showed...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00026 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591061404352512 |
|---|---|
| author | Cheng-Yu Tang Chueh-Chuan Yen |
| author_facet | Cheng-Yu Tang Chueh-Chuan Yen |
| author_sort | Cheng-Yu Tang |
| collection | DOAJ |
| description | The overexpression of myeloid cell leukemia-1 (MCL-1) has been identified in numerous hematologic malignancies and solid tumors. Currently, there are no selective MCL-1 inhibitors. Here, we present a case of left kidney undifferentiated spindle cell sarcoma with MCL-1 amplification. The tumor showed primary resistance to chemotherapy and immune checkpoint inhibitors. Combination therapy of bortezomib, venetoclax, and dexamethasone demonstrated a positive response, resulting in a stable tumor condition for 6 months. To our knowledge, this is the first report to mention the clinical efficacy of bortezomib, venetoclax, and dexamethasone therapy in an MCL-1-amplified solid tumor. |
| format | Article |
| id | doaj-art-cebf8ea8db8b486dbb434f5963364f74 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-cebf8ea8db8b486dbb434f5963364f742025-01-23T05:09:19ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062023-10-0110415415710.4103/ejcrp.eJCRP-D-23-00026Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone TherapyCheng-Yu TangChueh-Chuan YenThe overexpression of myeloid cell leukemia-1 (MCL-1) has been identified in numerous hematologic malignancies and solid tumors. Currently, there are no selective MCL-1 inhibitors. Here, we present a case of left kidney undifferentiated spindle cell sarcoma with MCL-1 amplification. The tumor showed primary resistance to chemotherapy and immune checkpoint inhibitors. Combination therapy of bortezomib, venetoclax, and dexamethasone demonstrated a positive response, resulting in a stable tumor condition for 6 months. To our knowledge, this is the first report to mention the clinical efficacy of bortezomib, venetoclax, and dexamethasone therapy in an MCL-1-amplified solid tumor.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00026bortezomibmyeloid cell leukemia-1 amplificationsarcomavenetoclax |
| spellingShingle | Cheng-Yu Tang Chueh-Chuan Yen Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy Journal of Cancer Research and Practice bortezomib myeloid cell leukemia-1 amplification sarcoma venetoclax |
| title | Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy |
| title_full | Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy |
| title_fullStr | Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy |
| title_full_unstemmed | Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy |
| title_short | Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy |
| title_sort | left kidney undifferentiated spindle cell sarcoma with myeloid cell leukemia 1 amplification therapeutic response to bortezomib venetoclax and dexamethasone therapy |
| topic | bortezomib myeloid cell leukemia-1 amplification sarcoma venetoclax |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00026 |
| work_keys_str_mv | AT chengyutang leftkidneyundifferentiatedspindlecellsarcomawithmyeloidcellleukemia1amplificationtherapeuticresponsetobortezomibvenetoclaxanddexamethasonetherapy AT chuehchuanyen leftkidneyundifferentiatedspindlecellsarcomawithmyeloidcellleukemia1amplificationtherapeuticresponsetobortezomibvenetoclaxanddexamethasonetherapy |